

## Treatment Review Decision-Making Table

Evidence Level	TIAC Review and Research Requirements	DHS 107 Language
<b>Level 1: Strong Evidence</b>	Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, National Professional Development Center) have approved of or rated the treatment package as having a strong evidence base; authorities are in agreement about the level of evidence. Minimum of two group studies or five single subject studies or a combination of the two. Studies were conducted across at least two independent research groups. Studies were published in peer reviewed journals. There is a published procedures manual for the treatment, or treatment implementation is clearly defined (i.e., replicable) within the studies. Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.	Proven and effective treatment for autism and/or other developmental disabilities
<b>Level 2: Moderate Evidence</b>	Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have approved of or rated the treatment package as having at least a minimal evidence base; authorities may not be in agreement about the level of evidence. Minimum of one group study or two single subject studies or a combination of the two. Studies were conducted by someone other than the creator/provider of the treatment. Studies were published in peer reviewed journals. Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.	Proven and effective treatment for autism and/or other developmental disabilities
<b>Level 3: Emerging Evidence</b>	Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have recognized the treatment package as having an emerging evidence base; authorities may not be in agreement about the level of evidence. May be one group study or single subject study. Study was conducted by someone other than the creator/provider of the treatment. Study was published in peer reviewed journal. Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.	Promising as a treatment for autism and/or other developmental disabilities
<b>Level 4: Insufficient Evidence</b>	Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence. Study was conducted by the creator/provider of the treatment. Study was not published in a peer reviewed journal. Participants (i.e., N) are not clearly identified as individuals with autism spectrum disorders or developmental disabilities.	Experimental treatment
<b>Level 5: Untested or Potential for Harm</b>	Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence. There are no published studies supporting the proposed treatment package. There exists evidence that the treatment package is potentially harmful (e.g., authoritative bodies have expressed concern regarding safety/outcomes; professional organizations or certifying bodies have created statements regarding safety/outcomes).	Experimental treatment